2013年8月2日骨科种植体厂家ConforMIS披露，其E轮融资已达到惊人的1.677亿美元，涵盖了美国、欧洲、亚洲和中东地区的顶级主权财富基金和私募股权基金。 ConforMIS将利用这笔资金将2代iTOTAL全膝关节置换系统商品化，同时寻求新的并购机会。

ConforMIS公司成立于2004年，是一家定制式膝关节置换系统制造商。iTOTAL全膝关节置换系统搭配iFIT图像测绘平台使用，可以为 每个病人设计合适的膝关节植入体。此前，患者仅可在一定范围内选择预制式的产品。该公司的CEO曾表示：“相信我们的技术将有可能改变整个骨科行业。”

ConforMIS Achieves Significant Funding Milestone with $167.7 Million in Series E Financing

Latest funding to support ongoing commercial expansion of iTotal® G2 rollout, the industry's only patient-specific total knee implant G2 rollout

Bedford, Mass. - August 2, 2013-- ConforMIS, Inc., a privately held medical device company pioneering patient-specific orthopedic implants, announced today it has expanded its Series E financing to $167.7 million with participation from top-tier Sovereign Wealth Funds, Government Investment Funds and Private Equity Funds in the U.S., Europe, Asia and the Middle East. ConforMIS will use the funds to expand its commercialization of the iTotal® G2 total knee replacement system in the U.S. and abroad, advance its manufacturing capabilities and invest in new market opportunities.

"With this round of financing, ConforMIS is well positioned to scale up our operations as we see great demand for our patient-specific knee implants," said Philipp Lang, M.D., CEO of ConforMIS. "We believe that our technology has the potential to revolutionize the orthopedics industry and we see the knee as only the first application of our proprietary iFit® image-to-implant platform. In addition, this funding provides the resources to pursue several strategic initiatives."

Since its founding in 2004, ConforMIS has been one of the fastest growing orthopedic companies on the strength of its patient-specific total and partial knee replacement systems. ConforMIS uses its iFit technology to design knee implants and instrumentation for each individual patient, a key difference from off-the-shelf standard implants used for decades that come in a limited range of sizes. By manufacturing implants designed to match each patient's unique size and shape, the company is addressing many of the primary causes of patient dissatisfaction common with traditional off-the-shelf total knee replacements. Sources of dissatisfaction with off-the-shelf implants include pain as a result of improper implant fit and functional limitations due to altered kinematics.

The company's patient-specific approach also includes a just-in-time delivery model that is unique in orthopedics, with a small sterile kit that contains the implants and disposable instruments for the procedure. This results in reduced hospital inventory management, lower sterilization costs and faster operating room set up and turnover. This contrasts with off-the-shelf implants that are stored locally at the hospital and come with six to eight trays of instruments that must be re-sterilized before each procedure.

For more information on ConforMIS visit conformis.com.    

About ConforMIS, Inc.

ConforMIS, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary technology is supported by more than 375 patents and patent applications in the areas of image processing, patient-specific implant systems, patient-specific surgical techniques, patient-specific instrumentation, and manufacturing across multiple joints.  ConforMIS' award winning solutions, the iUni® G2, iDuo® G2 and iTotal® G2, offer a personalized approach to knee replacement with unique benefits over traditional off-the-shelf implants. All devices have been cleared by the U.S. FDA for marketing in the US and CE Marked in Europe. Follow @ConforMIS and become a fan on Facebook.

Brittany Falconer
Racepoint Group
617-624-3242
conformis@racepointgroup.com